

## animal research at DRDC Downsview: a hidden history



DRDC Downsview is one of eight Federal military research facilities. a brief overview is here:

[https://en.wikipedia.org/wiki/DRDC\\_Toronto](https://en.wikipedia.org/wiki/DRDC_Toronto)

apparently the Downsview location no longer conducts animal tests. i wrote them in April 2018, hoping to arrange the transfer of “spent” lab animals from Downsview to Ontario animal sanctuaries. The Armed Forces Public Inquiry Desk wrote me back on May 1, claiming that “the DRDC Toronto lab in Downsview no longer has an animal facility/capability.”

DRDC animal facilities in Suffield [Alberta] and the Maritimes are still active.

so the appended docs - secured by Liz White and Animal Alliance Canada thru an ATIP request - offer a peek into the historic practices at Downsview [2004 to 2007], and indicate, perhaps, some of on-going research at other DRDC sites in Canada.

the docs reveal:

- “yearly basic trauma-related procedures” : practicing **on pigs** “different surgical procedures”, “performed under various combinations of stressors”
- tests on a “proprietary gel” they’ve developed for treating burn wounds, on **130 rats**
- testing another “proprietary wound care agent using a porcine model of partial thickness wounds” on 17 Yorkshire pigs
- “Evaluation of hemostatic agents and dressing materials using an acute rat model of moderate liver hemorrhage” : on **600 rats**
- a “partial-thickness burn wounds” study, again, for a “proprietary gel”: on **260 rats**. they note that “This scald model has been used in previous DRDC experiments”. their method of “Euthanasia” is “Cervical Dislocation under anaesthesia”. they also assure the CCAC that “Animals that will lose more than 15% WB, show signs of withdrawal, abnormal breathing rate, undue pain or distress will be sacrificed. The animals will be humanely euthanized within 24 h following burn injury if the nature of the signs of illness (hunched position, reduced muscle tone, lack of planar reflex), their rate of onset and a marked hypothermia (<33C) strongly suggest impending death.”
- a pilot study on **215 New Zealand rabbits** “to assess the feasibility of establishing a reliable rabbit model of liver hemorrhage; and 2) determine the hemostatic efficacy of various hemostatic agents”
- a study “to establish a non-lethal model of contaminated open wounds in pigs” on up to **21 Yorkshire pigs**. their justification of species choice: “The pig is used extensively in animal models of wound healing since pig skin is very similar to that of humans.”

DRDC Downsview once maintained an in-house rat colony. they brought in rabbits, pigs, and other rats for a variety of experiments.

DRDC is a voluntary member of the Canadian Council on Animal Care, which means they file overviews of their research protocols with the CCAC to get the “humane” seal of approval. it’s these CCAC applications which Liz managed to get through her ATIP request. they took three years to send her anything, and some of it is blanked out, e.g. names of researchers & suppliers.

some of it is, surprisingly, not blanked out: room numbers in the building where they kept the animals, and room numbers where the experiments took place.

many of these studies involved experiments at the CCAC's Category D: which is their second-highest category, second-most "invasive". note that even Category B studies ["Experiments which cause little or no discomfort or distress"] can involve

domestic flocks or herds being maintained in simulated or actual commercial production management systems; the short-term and skillful restraint of animals for purposes of observation or physical examination; blood sampling; injection of material in amounts that will not cause adverse reactions by the following routes: intravenous, subcutaneous, intra-muscular, intraperitoneal, or oral, but not intrathoracic or intracardiac (Category C); acute non-survival studies in which the animals are completely anesthetized and do not regain consciousness; approved methods of euthanasia following rapid unconsciousness, such as anesthetic overdose, or decapitation preceded by sedation or light anesthesia; short periods of food and/or water deprivation equivalent to periods of abstinence in nature.

[from [CCAC Policy Statement](#)]

the DRDC may tell you their research is to protect Canadians and help "our peacekeepers" around the globe. the Defence Corporate Secretary, Isabelle Daoust, wrote me on behalf of our Minister of Defence on May 15:

DND precisely adheres to the CCAC guidelines and internationally accepted protocols to ensure the ethical treatment of animals and that the use of animals is weighed against the acknowledged benefits to the Canadian Armed Forces.

regarding the 2005 study of liver hemorrhage, on 600 rats, the DRDC notes: "Operations Enduring Freedom [the U.S. term for their global 'war on terrorism'] and Iraqi Freedom [the U.S. term for the second Iraq War] have recommended further study to develop solutions for treatment of non-compressible hemorrhage." the links between peacekeeping and the interests of U.S. empire seem close, here.

Animal Alliance has an ongoing campaign to end the use of animals in Canadian military research, focused on the use of pigs in trauma training:

<https://www.animalalliance.ca/campaigns/other-campaigns/military-trauma-training/>



from the CRDC medic-training program, held annually.

appendix: the Downsview docs

## form A [2006-2007]

trauma training for medics/medical officers, using pigs. a study in Ottawa, replicating field work in Toronto. DRDC Toronto was asked by [blanked out] to organize a similar field test at [blanked out] in Ottawa

“yearly basic trauma-related procedures” for medics and medical officers were already held at DRDC Toronto that year [i.e. 2006?]


here’s the protocol overview:

“Up to two male Yorkshire pigs (70-75 kg) will be obtained from [blank], 4-6 times a year. Large pigs are considered the best alternative to using primates when performing trauma-related procedures. The surgical procedures [. . .] will be performed within 3-6 h of the animals being delivered at [blanked out] The animals will be: fasting for 24 h (instructions will be provided to the supplier); have free access to water until their pre-anaesthesia; and, temporarily, housed in a room that will provide 2-4 m<sup>2</sup> of pen space per animal, part of the floor being covered with straw. Following pre-anaesthesia with ketamine (15 mg/kg body weight, i.m.) and acepromazine (0.5 mg/kg body weight, i.m.), the animals will be lifted on a trolley, covered with a blanket, and, wheeled outside the building to a secluded area. The different surgical procedures will then be performed under various combinations of stressors”

s.15(1)

s.17

s.19(1)



PROTOCOL NO. 12/00

FOR OFFICE USE ONLY  
 Expiry Date

**1**

Surname	First Name	Initial
Rank/Position	Section	Group
DS 54	Operational Medicine/MS	Trauma
DCIEM Telephone	Residence Telephone	
NAME OF DESIGNATED ALTERNATE(S) FOR EMERGENCIES		
Name	DCIEM Telephone	Residence Telephone
Name	DCIEM Telephone	Residence Telephone

**2**

Title

Establishment of a non-lethal model of full thickness contaminated wound in pigs Surgical skills practicum et

**3**

PROPOSED START DATE OF RESEARCH	Day	Month	Year
	01	Apr/May	2003†
EXPECTED DATE OF COMPLETION	Day	Month	Year
	310	Apr/Mar	2007‡

**4**

CATEGORY OF INVASIVENESS (Refer to Canadian Council on Animal Care Categories A, B, C, D, E).

B. Shaving (under anaesthesia)       BC. Wound-injury (under anaesthesia)

B. Pre-med, mild discomfort, I.m. Injection       D. Recovery from wound-injury

LIST EACH experimental condition or manipulation that could cause pain or discomfort in the conscious animal and for each indicate the expected degree of pain/discomfort using the CCAC Codes.  
 FOR EACH, indicate (by checking the box) the conditions that will be alleviated and ensure that the drugs to be used are stated in Section 13 and procedures described in Section 6.

**5**

TYPE OF EXPERIMENT	<input type="checkbox"/> <input checked="" type="checkbox"/>	Research <input checked="" type="checkbox"/> <input type="checkbox"/>	Testing
SURGICAL	<input checked="" type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/>	Survival
Acute	<input type="checkbox"/> <input checked="" type="checkbox"/>		NON-SURGICAL <input checked="" type="checkbox"/> <input type="checkbox"/>
	Acute	Chronic	

FUNDING SOURCE NUMBER: 16ca10FE code (TBD) Thrust 20cf \_\_\_\_\_ (i.e., Financial Coding, WBE)

PEER-REVIEWED   YES   NO IF YES, ATTACH REVIEW DOCUMENTATION.

The experimental procedures described herein represent standards protocols in the ATLS manual (ACS-COT, 1997).

IF PROTOCOL IS SUBMITTED BETWEEN SCHEDULED ACC MEETINGS, IT MAY BE GIVEN 'PROVISIONAL' APPROVAL BY THE CHAIR, SECTION HEAD, VETERINARIAN, AND COMMUNITY MEMBER COLLECTIVELY. A COPY, HOWEVER, MUST BE SUBMITTED TO ALL MEMBERS OF THE COMMITTEE AT THAT TIME FOR FORMAL APPROVAL AT THE NEXT MEETING.

s.15(1)

s.17

- 1. Make up to 5 lacerations on the animal and suture of laceration(s)
- 2. Suture of laceration(s) Intravenous cannulation for administration of saline or other clinically-approved fluid (e.g., HSD)
- 3. Intraosseus cannulation for administration of fluids (maybe)

Formatted: Bullets and Numbering

- 4. Needle decompression of the chest
- 5. Chest tube insertion Intravenous/intraosseous cannulation for administration of saline or other clinically-approved fluid (e.g., HSD)

Formatted: Bullets and Numbering

Needle and surgical cricothyroidotomy

Formatted: Bullets and Numbering

- 6. Femoral venous or arterial injury, followed by:

Formatted: Bullets and Numbering

a. Application of hemostatic agents such as

OR) along with pressure dressing;

b. Placement of tourniquet

- 7. Needle and surgical cricothyroidotomy (note: this procedure is listed last as it can be performed once the animal has been euthanized)

Application of hemostatic agents such as

Formatted: Bullets and Numbering

OR) along with pressure

dressing;

Placement of tourniquet

Formatted: Bullets and Numbering

Laceration & suturing (see Annex C: 60 min);

Formatted: Bullets and Numbering

Intraosseous puncture (see Annex F: 30 min); (maybe)

Venous cutdown (see Annex B: 60 min);

Central venous puncture (see Annex A: 30 min);

Needle thoracocentesis (see Annex D: 30 min);

Chest tube insertion (see Annex E: 60 min);

Femoral venous or artery injury

Needle and surgical cricothyroidotomy; see Annex G: 60 min);

Thoracotomy

Laparotomy

After completion of all surgical procedures (i.e., approximately 5 h), the animals will be humanely euthanized using T61 (i.v.). staff will then disposed of the animal carcasses according to DRDC standard operating procedures.

See Annex A:

Staff involved

. will be travel to at to provide animal care and performing all pre-operative procedures (e.g., anesthesia induction; analgesic administration).

(a surgeon of 1 Cdn Field Hospital) will be responsible for supervising all experimental procedures.

Yearly, up to medical assistants at will be performing the different experimental procedures.

Formatted

Reference

Formatted

Formatted: Bullets and Numbering





s.15(1)

s.17

**12** SPECIAL ANIMAL CARE REQUIREMENTS. Specify, if any, special housing, nutritional, temperature, lighting, post-operative care or other facilities or conditions that are or may be required.

~~The animals will be used within 3-6 allowed to adapt to the environment conditions (20-25°C, 12 h light/dark cycle) for at least 7 days before h of undergoing surgery. Animals will be fasting, housed individually, and will have free access to pig chow and water during the study until pre-anaesthesia; and...~~

~~All experimental procedures will be conducted in the Animal Care Facilities at \_\_\_\_\_ Daily injection of long-lasting analgesics for 21-d or as required.~~

SPECIFY ANIMAL HOUSING ROOM ~~N/A~~ To be determined upon visit from DRDC Toronto Staff of facilities 446  
SPECIFY EXPERIMENTAL SITE ROOM ~~N/A~~ Outside in secured area (see previous comment) 04

**13** DRUGS FOR ANAESTHESIA/ANALGESIA  
Is Anaesthesia to be used?  YES  NO Is Analgesia to be used?  YES  NO

If yes, complete Section 13 below. If no to either, justification is in Section 6 para

	DRUG	DOSAGE	ROUTE OF ADMINISTRATION
A. Pre-Anaesthesia	Ketamine	15 mg/kg BW	i.m.
Pre-Anaesthesia	acepromazine	0.5 mg/kg BW	i.m.
B. Anaesthesia	Ketamine halothane/N2O	22 mg/kg BW, to effect	effect effect inhalation i.m.
Anaesthesia	acepromazine	0.5 mg/kg BW, to effect	i.m.
C. Pre-Analgesic	buprenorphine Fentanyl	0.1-0.3 mg/kg, 0.50 mg/kg	patch i.m.
Post-Analgesic	buprenorphine	0.1-0.3 mg/kg	i.m.
D. Other			

POST-OPERATIVE CARE needs defined in Section 12 are fully detailed in Section 6 para ~~Annex A p. 4-13-15.~~ NOT APPLICABLE.

**EUTHANASIA**

**14**  ~~Anesthetic overdose/ Sedation with i.v. T61 under inhalation~~ NOTE: Physical euthanasia can be used only with pre-anaesthesia. If this is

- ~~Ketamine rompun (in) than iv, T61~~ not possible, justification must be included:
  - Cervical Dislocation  Decapitation  Pitling  Other
  - Exsanguination (under Anaesthesia)
  - Stunning
  - Carbon Dioxide
- IF NOT EUTHANIZED, please indicate how and where disposed of:

**HAZARDOUS AGENTS AND PRECAUTIONS**

**15** Specify each Agent and Potential Hazard (include amount, route, and Frequency of admin, precautions OR indicate if Included in Section 6). NOT APPLICABLE

- Biological Ps. aeruginosa, Staph. epidermis, Fusobacterium
- Chemical
- Carcinogen
- Radioisotope/Radiation (include R/A Permit No. and Expiration Date)

NOTE: If special precautions are required, ensure these are detailed in Section 12.

**16** ENDPOINTS  
Specify Endpoints and Criteria (in detail):

~~All animals will be closely examined and weighed daily. Animals that will lose more than 15% of their BW, show signs of withdrawal, abnormal breathing rate, fever or undue pain or distress will be euthanized.~~  
NOT APPLICABLE.





## form B [2005]

protocols for a series of wound studies involving rats and pigs. from what i can tell, over a thousand rats and 44 pigs.

e.g. study “of full thickness, contaminated wounds in pigs” on 21 Yorkshire pigs

tests on a “proprietary gel” they’ve developed for treating burn wounds, on 130 rats. possible incorporation of gel into field first aid kits for CF soldiers.

testing another “proprietary wound care agent using a porcine model of partial thickness wounds”: 17 Yorkshire pigs.

on 600 rats: “Evaluation of hemostatic agents and dressing materials using an acute rat model of moderate liver hemorrhage.”

ANIMAL USE DATA FORM

Year: 2005

Institution Name: DEFENCE R&D CANADA (DRDC TORONTO) Institution Code: MG01

Protocol No.	CI <sup>1</sup>	Investigator	Protocol Description <sup>2</sup>	PAU*	Species	AA <sup>3</sup>	AUN <sup>4</sup>
2/01	B		Health surveillance program. One or two rats in each room will be identified as sentinels and not used for experimental purposes. Under general anaesthesia, a blood sample for serological testing will be obtained by cardiac puncture. Serum samples will be prepared and tested in-house using the Murine ImmunoComb Kit and, if necessary, serology profiles will be performed by	2	Sprague-Dawley Rat	20	0
<del>1/04</del>	<del>D</del>		<del>Evaluation of the wound-healing properties of a proprietary gel in a rat model of uncontaminated, partial thickness burn wounds. The unique combination of properties in the gel, if confirmed experimentally, would make the product a valuable candidate for incorporation into the DRDC Toronto biomaterial for use in field first aid kits for CF soldiers.</del>	<del>2</del>	<del>Sprague-Dawley Rat</del>	<del>130</del>	<del>0</del>
2/04	D		Establishment of non-lethal model of full thickness, contaminated wounds in pigs. Delays in providing adequate therapy for open wounds continues to result in high infection rates and infectious complications. The trauma model developed will be used in future studies to evaluate the efficacy of wound-care agents.	2	Yorkshire Pig	21	3
3/04	D		Standard operating procedures in rats for the evaluation of wound-care agents, including dressings, formulations and antimicrobial agents. The standard operating procedure developed will be used in future studies to determine the bactericidal efficacy. Preliminary testing will be carried out using a four-wound model of infection. Final testing of the compound/dressing under study will be performed using a modification of the rat model developed under ACC 1/98.	2	Sprague-Dawley Rat	450	378
4/04	D		Evaluation of the wound-healing properties of a proprietary wound care agent using a porcine model of partial thickness wounds. In vitro experiments performed previously confirmed the bactericidal properties of a proprietary gel formulation. This protocol will assess the wound healing properties of the gel in a porcine model. If the results are conclusive, the wound-healing of the DRDC Toronto biomaterial loaded with the active ingredients of the gel will be assessed.	2	Yorkshire Pig	17	4 (3R)
5/04	B		Evaluation of hemostatic agents and dressing materials using an acute rat model of moderate liver hemorrhage. Uncontrolled bleeding remains a major cause of death in combat. First responders still have limited means to stop truncal hemorrhage. Hemostatic dressings have proven useful where it is possible to mechanically suppress bleeding and they are expensive. has caused concerns related to high temperatures generated during the chemical process leading to hemostasis so it is not recommended for soft internal tissues. Operations Enduring Freedom and Iraqi Freedom have recommended further study to develop solutions for treatment of non-compressible hemorrhage.	2	Sprague-Dawley Rat	600	0
1/05	B			5	Yorkshire Pig	6	2

A protocol may contain more than one purpose, species and/or level of invasiveness - each should be listed separately, using the same protocol number.

+ The protocol number, protocol title, name of investigator and name of institution will be kept confidential in all cases. The remaining information will be used in the preparation of annual statistics on the use of animals in Canadian science.

<sup>1</sup> CI Category of Invasiveness

<sup>2</sup> Protocol Description Please give a descriptive protocol title that indicates, in lay terms, the nature of the procedures used (preferably in 40 words or less)

<sup>3</sup> AA No. of Animals Approved

## form C [2004 - 2005]

“partial-thickness burn wounds” in rats. again, for a “proprietary gel”

not peer-reviewed

“The veterinary technician will also be responsible for performing all burn procedures after adequate training from [blacked out]

manufacturer of DRDC dressing is blanked out

“This scald model has been used in previous DRDC experiments”

130 x 2 rats [half bred in-house]

weirdly, they list the

Animal Housing Room: 1412

Experimental Site Room: 1404

method of “Euthanasia” is “Cervical Dislocation under anaesthesia”

“Animals that will lose more than 15% WB, show signs of withdrawal, abnormal breathing rate, undue pain or distress will be sacrificed. The animals will be humanely euthanized within 24 h following burn injury if the nature of the signs of illness (hunched position, reduced muscle tone, lack of planar reflex), their rate of onset and a marked hypothermia (<33C) strongly suggest impending death.”

s.15(1)

s.17

s.19(1)



# DRDC TORONTO

## ANIMAL USE PROTOCOL

PROTOCOL NO. 1/04

FOR OFFICE USE ONLY  
Expiry Date

1	Surname	First Name	Initial
	Rank/Position DS-4	Section OM	Group TG
	DRDC Telephone	Residence Telephone	
NAME OF DESIGNATED ALTERNATE(S) FOR EMERGENCIES			
	Name	DCIEM Telephone	Residence Telephone
	Name	DCIEM Telephone	Residence Telephone

2	Title
	Evaluation of the wound-healing properties of a proprietary gel in a rat model of uncontaminated, partial-thickness burn wounds

3	PROPOSED START DATE OF RESEARCH	Day 01	Month 10	Year 04
	EXPECTED DATE OF COMPLETION	Day 31	Month 12	Year 05

4	CATEGORY OF INVASIVENESS (Refer to Canadian Council on Animal Care Categories A, B, C, D, E).		
	D Burn Injury	B s.c. injection analgesic	<input type="checkbox"/>
	B		<input type="checkbox"/>
LIST EACH experimental condition or manipulation that could cause pain or discomfort in the conscious animal and for each indicate the expected degree of pain/discomfort using the CCAC Codes. FOR EACH, indicate (by checking the box) the conditions that will be alleviated and ensure that the drugs to be used are stated in Section 13 and procedures described in Section 6.			

5	TYPE OF EXPERIMENT	<input type="checkbox"/> Research	<input checked="" type="checkbox"/> Testing
	SURGICAL	<input type="checkbox"/> Acute	<input checked="" type="checkbox"/> Survival
	NON-SURGICAL	<input checked="" type="checkbox"/> Acute	<input type="checkbox"/> Chronic

FUNDING SOURCE NUMBER: 30dd05 (i.e., Financial Coding, WBE)

PEER REVIEWED  YES  NO IF YES, ATTACH REVIEW DOCUMENTATION.

NOTE 1. AN INDEPENDENT PEER REVIEW OF SCIENTIFIC MERIT IS REQUIRED FOR ALL NEW RESEARCH PROJECTS.

This protocol has previously been submitted

NOTE 2. IF A PROTOCOL IS SUBMITTED BETWEEN SCHEDULED ACC MEETINGS, IT MAY BE GIVEN 'PROVISIONAL' APPROVAL BY THE CHAIR, SECTION HEAD, VETERINARIAN, AND COMMUNITY MEMBER COLLECTIVELY. A COPY, HOWEVER, MUST BE SUBMITTED TO ALL MEMBERS OF THE COMMITTEE AT THAT TIME FOR FORMAL APPROVAL AT THE NEXT MEETING.



---

**6 DESCRIPTION OF PROJECT AND PROCEDURES.** Describe in **DETAIL** all procedures, techniques to be used, emphasizing those performed on animals. Include all justifications required from Sections 7-16. Append additional page(s) as necessary.

See document enclosed for details of experimental procedures.

\_\_\_\_\_ and the \_\_\_\_\_ will be responsible for performing all pre-operative procedures, incl. anesthesia induction; analgesic administration. The veterinary technician will also be responsible for performing all burn procedures after adequate training from \_\_\_\_\_

Co-op students : \_\_\_\_\_ will initially be responsible for preparation of gel formulations, care of animals during acclimation period, and post-operative observation of the animals. After an appropriate period of observation (i.e., at least 16 animals having undergone the burn protocol), they will take over \_\_\_\_\_ duties (i.e., pre-operative procedures described above only).

An on-call staff from \_\_\_\_\_ familiar with the i.p. injection of capsaicin in newborn rats, will be responsible for performing this technique.

s.15(1)

s.17

**7 IDENTIFY THE PRIMARY OBJECTIVE(S) OF THE PROJECT.** In layman's terms, please summarize the primary objective(s) and benefit(s) expected from the study.  
 The objective of the present study is to determine whether a 6-h application of the 2<sup>nd</sup> generation of DRDC dressing, now manufactured by [redacted] exerts any changes in whole body or skin temperature in a non-lethal rat model of non-contaminated burn wounds. This scald model has been used in previous DRDC experiments (ACC 1/97 amendment #2).

**8**

Name	Prof	Tech	PD	Grad	UnderGrad	Term	Training
	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Co-op students	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
(TBD)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Research Staff

Note: University one-day course, at minimum, is mandatory for all personnel, including students, post-docs, visiting fellows, RAS. Check if the individual has completed this or equivalent training.  
 Note: The appended experimental methods should indicate the responsibilities of each individual listed above.

**9**

Animal Species (Common Name)	Total Number of Animals	Source of Animals
Rat	130	
Rat	130	bred in house

Animals

**10 JUSTIFICATION FOR:** A. Species (see Note 1) and B. Number of Animals Used (See Note 2)

A. The rat species has been used extensively in studies of burn injury, especially for testing wound-care products.

B. The number of animals per experimental group should yield sufficient data for completing statistical analysis.

Note 1: Is the choice of animal the most scientifically appropriate one, and of the lowest level of sentience consistent with the Objectives? Justified in Section 6 ~~annex A p. 11-15-23~~

Note 2: Is the number of animals based on a plan incorporating statistical considerations that ensure sufficient, but not Excessive numbers for drawing reliable conclusions? Justified in Section 6 ~~annex A p. 11-15-27~~

**11 ALTERNATIVES:** Are non-animal alternatives available for this project?  YES  NO

12 SPECIAL ANIMAL CARE REQUIREMENTS. Specify, if any, special housing, nutritional, temperature, lighting, post-operative care or other facilities or conditions that are or may be required.  
 N/A

SPECIFY ANIMAL HOUSING ROOM 1412

SPECIFY EXPERIMENTAL SITE ROOM 1404

13	DRUGS FOR ANAESTHESIA/ANAGESIA	DRUG	DOSAGE	ROUTE OF ADMINISTRATION
A.	Pre-Anaesthesia			
	Pre-Anaesthesia			
B.	Anaesthesia	Halothane	to effect	inhalation
	Anaesthesia	nitrous oxide	to effect	inhalation
C.	Pre-Analgesic	buprenorphine	50 ug/kg	s.c.
	Post-Analgesic			
D.	Other			

POST-OPERATIVE CARE needs defined in Section 12 are fully detailed in annex A p. 2 I. 12-13 .  
 If anaesthesia or analgesia NOT TO BE USED in invasive protocol, justification in Section 6 para

14 Euthanasia

Anaesthetic Overdose (specify agent) NOTE: Physical euthanasia can be used only with pre-anaesthesia. If this is not possible, justification must be included:

Cervical Dislocation under anaesthesia  Decapitation  Pithing  Other

Exsanguination (under Anaesthesia) IF NOT EUTHANIZED, please indicate how and where disposed of:

Stunning

Carbon Dioxide

15 HazMat Specify each Agent and Potential Hazard (include amount, route, and Frequency of admin, precautions OR indicate if included in Section 6). NOT APPLICABLE

- Biological
- Chemical
- Carcinogen
- Radioisotope/Radiation (Include R/A Permit No. and Expiration Date)

NOTE: If special precautions are required, ensure these are detailed in Section 12.

16 Endpoints Specify Endpoints and Criteria (in detail):

All animals will be closely examined and weighed daily. Animals that will lose more than 15% WB, show signs of withdrawal, abnormal breathing rate, undue pain or distress will be sacrificed. The animals will be humanely euthanized within 24 h following burn injury if the nature of the signs of illness (hunched position, reduced muscle tone, lack of plantar reflex), their rate of onset and a marked hypothermia (<33C) strongly suggest an impending death.

Defining humane endpoints is imperative if the project will lead to pain or discomfort or any physical or physiological abnormality that would affect the animal's well-being. The criteria that will be employed to remove the animal from the study and euthanized prior to the onset of unrelievable pain or distress, morbidity or death MUST be stated here and in the protocol.

Declaration

All animals in this research/testing proposal will be maintained and used in accordance with the recommendations of the Canadian Council on Animal Care, the requirements under the Animals for Research Act, R.S.O. 1980, and the DCIEM Animal Care Policies And Guidelines, and other applicable DCIEM policies and procedures.

\_\_\_\_\_  
Principal Investigator

\_\_\_\_\_  
Date

Mgt Approval

\_\_\_\_\_  
Section or Group Head

\_\_\_\_\_  
Date

ACC Approval

\_\_\_\_\_  
Chair/Animal Care Committee

\_\_\_\_\_  
Date

\_\_\_\_\_  
DCIEM Consultant Veterinarian

\_\_\_\_\_  
Date

OBSERVATIONS, RESTRICTIONS OR CONDITIONS (as applicable). INCLUDE THE NEED FOR (and details of) EXTERNAL PEER REVIEW.

THIS PROTOCOL IS APPROVED FOR THE PERIOD SPECIFIED IN SECTION 3. IT WILL BE REVIEWED SEMI-ANNUALLY AT SCHEDULED DCIEM ACC MEETINGS. IF AN EXTENSION IS REQUIRED, A FORMAL AMENDMENT TO THE PROTOCOL MUST BE SUBMITTED FOR APPROVAL BY THE SECTION HEAD, CHAIR AND VETERINARIAN.

## form D [2006]

box check: "liver injury"

blacked-out but readable: "The objectives of this protocol are to 1)perform a pilot study to assess the feasibility of establishing a reliable rabbit model of liver hemorrhage; and 2) determine the hemostatic efficacy of various hemostatic agents"

on 215 [maximum] New Zealand rabbits

Source of Animals: blanked

justified in part because "there are currently no in vitro model [sic] simulating bleeding time."

euthanasia: intracardiac [injection into heart]

looks like there's no relevant post-operative care - the liver laceration is under surgical anaesthesia, and the animal is killed by intracardial injection on the operating table. from what i can tell.

s.15(1)  
 s.17  
 s.19(1)



**DRDC Toronto**

PROTOCOL NO. 2/06

**ANIMAL USE PROTOCOL**

FOR OFFICE USE ONLY  
 Expiry Date

**1**

Surname	First Name	Initial
Rank/Position DCS5	Section OMS	Group Trauma
DCIEM Telephone	Residence Telephone	
NAME OF DESIGNATED ALTERNATE(S) FOR EMERGENCIES		
Name	DRDC Telephone	Residence Telephone
Name	DRDC Telephone	Residence Telephone

**2**

Title

Evaluation of hemostatic agents using an acute rabbit model of moderate liver hemorrhage

**3**

PROPOSED START DATE OF RESEARCH	Day 1	Month March	Year 2006
EXPECTED DATE OF COMPLETION	Day 31	Month Dec	Year 2006

**4**

CATEGORY OF INVASIVENESS (Refer to Canadian Council on Animal Care Categories A, B, C, D, E).

B. shaving (under anesthesia)       B. Intracardiac injection of 1:6000 (under anesthesia)

B. Liver injury (under anesthesia)       B. ear vein cannulation (Under anesthesia)

LIST EACH experimental condition or manipulation that could cause pain or discomfort in the conscious animal and for each indicate the expected degree of pain/discomfort using the CCAC Codes.  
 FOR EACH, indicate (by checking the box) the conditions that will be alleviated and ensure that the drugs to be used are stated in Section 13 and procedures described in Section 6.

**5**

TYPE OF EXPERIMENT       Research       Testing

SURGICAL     Acute     Survival      NON-SURGICAL       Acute       Chronic

FUNDING SOURCE NUMBER: 16ci01; 30dd05      (i.e., Financial Coding, WBE)

PEER REVIEWED     YES       NO      IF YES, ATTACH REVIEW DOCUMENTATION.

IF PROTOCOL IS SUBMITTED BETWEEN SCHEDULED ACC MEETINGS, IT MAY BE GIVEN 'PROVISIONAL' APPROVAL BY THE CHAIR, SECTION HEAD, VETERINARIAN, AND COMMUNITY MEMBER COLLECTIVELY. A COPY, HOWEVER, MUST BE SUBMITTED TO ALL MEMBERS OF THE COMMITTEE AT THAT TIME FOR FORMAL APPROVAL AT THE NEXT MEETING.

6

DESCRIPTION OF PROJECT AND PROCEDURES. Describe in DETAIL all procedures, techniques to be used; emphasizing those performed on animals. Append additional page(s) as necessary.

~~See Annex A~~

~~will perform all pre-operative procedures (anesthesia induction, analgesic administration)~~

~~will perform the surgical procedures (liver resection)~~

~~Co-ops students~~

~~will be responsible for shaving procedures (after adequate training from)~~

s.15(1)

s.17

**7** IDENTIFY THE PRIMARY OBJECTIVE(S) OF THE PROJECT. In layman's terms, please summarize the primary objective(s) and benefit(s) expected from the study.

The objectives of this protocol are to: 1) perform a pilot study to assess the feasibility of establishing a reliable rabbit model of liver hemorrhage; and 2) determine the hemostatic efficacy of various hemostatic agents.

**8** RESEARCH STAFF

Name	Prof	Tech	PD	Grad	UnderGrad	Term	Training
	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Note: University one-day course, at minimum, is mandatory for all personnel, including students, post-docs, visiting fellows, RAS. Check if the individual has completed this or equivalent training.  
 Note: The appended experimental methods should indicate the responsibilities of each individual listed above.

**9** ANIMALS

Animal Species (Common Name)	Total Number of Animals	Source of Animals
New Zealand rabbit	Max: 215	

**10** JUSTIFICATION FOR: A. Species (see Note 1) and B. Number of Animals Used (See Note 2)

A. Rabbits have been successfully used to demonstrate the efficacy of hemostatic agents applied to liver wounds.

B. Number of animals used in each study is based on a maximum number of 15 rabbits per experimental group to yield sufficient data for completing statistical analysis (95% confidence interval, based on sample size, average blood loss and variability reported in this study).

Note 1: Is the choice of animal the most scientifically appropriate one, and of the lowest level of sentience consistent with the Objectives? Justified in Section 6, Annex 4 (p. 11, 20, 26) and p. 31, 42, 44.

Note 2: Is the number of animals based on a plan incorporating statistical considerations that ensure sufficient, but not Excessive numbers for drawing reliable conclusions? See justification in B above.

**11** ALTERNATIVES: Are non-animal alternatives available for this project?  YES  NO

There are currently no in vitro model simulating bleeding time.



**12** SPECIAL ANIMAL CARE REQUIREMENTS. Specify, if any, special housing, nutritional, temperature, lighting, post-operative care or other facilities or conditions that are or may be required.

N/A

SPECIFY ANIMAL HOUSING ROOM 147

SPECIFY EXPERIMENTAL SITE ROOM 1404A (surgical suite)

**13** DRUGS FOR ANAESTHESIA/ANALGESIA

Is Anaesthesia to be used?  YES  NO Is Analgesia to be used?  YES  NO

If yes, complete Section 13 below. If no to either, justification is in Section 6 para

	DRUG	DOSAGE	ROUTE OF ADMINISTRATION
A. Pre-Anaesthesia Pre-Anaesthesia			
B. Anaesthesia Anaesthesia	<u>isoflurane</u>	to effect	inhalation
C. Pre-Analgesic Post-Analgesic	<u>buprenorphine</u>	<u>0.02-0.05 mg/kg</u>	<u>sc</u>
D. Other			

POST-OPERATIVE CARE needs defined in Section 12 are fully detailed in Section 6 para N/A.

**14** EUTHANASIA

- Anaesthetic Overdose (specify agent)
  - Cervical Dislocation
  - Exsanguination (under Anaesthesia)
  - Stunning
  - Carbon Dioxide
- NOTE: Physical euthanasia can be used only with pre-anaesthesia. If this is not possible, justification must be included:
- Decapitation
  - Pithing
  - Other intracardiac
- IF NOT EUTHANIZED, please indicate how and where disposed of:

**15** HAZARDOUS AGENTS AND PRECAUTIONS

Specify each Agent and Potential Hazard (include amount, route, and Frequency of admin, precautions OR indicate if included in Section 6). NOT APPLICABLE

- Biological
- Chemical
- Carcinogen
- Radioisotope/Radiation (include R/A Permit No. and Expiration Date)

NOTE: If special precautions are required, ensure these are detailed in Section 12.

**16** ENDPOINTS

Specify Endpoints and Criteria (in detail):

N/A

Defining humane endpoints is imperative if the project will lead to pain or discomfort or any physical or physiological abnormality that would affect the animal's well-being. The criteria that will be employed to remove the animal from the study and euthanized prior to the onset of unrelievable pain or distress, moribundity or death MUST be stated here and in the protocol.

---

**DECLARATION**

All animals in this research/testing proposal will be maintained and used in accordance with the recommendations of the Canadian Council on Animal Care, the requirements under the Animals for Research Act, R.S.O. 1980, and the DCIEM Animal Care Policies And Guidelines, and other applicable DCIEM policies and procedures.

\_\_\_\_\_  
Principal Investigator

\_\_\_\_\_  
Date

---

**MANAGEMENT APPROVAL**

\_\_\_\_\_  
Section or Group Head

\_\_\_\_\_  
Date

---

**ANIMAL CARE COMMITTEE APPROVAL**

\_\_\_\_\_  
Chair/Animal Care Committee

\_\_\_\_\_  
Date

\_\_\_\_\_  
DCIEM Consultant Veterinarian

\_\_\_\_\_  
Date

---

**OBSERVATIONS, RESTRICTIONS OR CONDITIONS** (as applicable). INCLUDE THE NEED FOR (and details of) EXTERNAL PEER REVIEW.

THIS PROTOCOL IS APPROVED FOR THE PERIOD SPECIFIED IN SECTION 3. IT WILL BE REVIEWED SEMI-ANNUALLY AT SCHEDULED DCIEM ACC MEETINGS. IF AN EXTENSION IS REQUIRED, A FORMAL AMENDMENT TO THE PROTOCOL MUST BE SUBMITTED FOR APPROVAL BY THE SECTION HEAD, CHAIR AND VETERINARIAN.

## form E [probably 2006]

more detail on rabbit hemorrhage study - likely the study of 2006 in Form D

looks like they tried with rats but had trouble because "this species possesses an enormous ability to control even massive bleeding (e.g., 30% total blood volume shed) without the need for further adjuncts, a finding recently confirmed by another scientist"


after "liver-resection", bleeding is monitored for 30 mins, "after which period they will be humanely euthanized by intracardiac injection of T-61."

ACC 2-06

ATLAS OF SURGICAL OPERATIONS

11th Edition  
**ATLAS  
OF SURGICAL  
OPERATIONS**

ZOLLINGER / ZOLLINGER

SUNNYBROOK  
  
92883393  
Health Sciences Library

Evaluation of hemostatic agents using  
an acute rabbit model of moderate liver hemorrhage

*Introduction*

5 Uncontrolled bleeding remains a major cause of death in combat, up to  
25% of the evacuated casualties dying of hemorrhagic complications at the first  
echelon hospital. Up to 90% of all hemorrhagic deaths in Vietnam were from  
truncal injury. First responders still have limited means at their disposal to stop  
truncal hemorrhage. While hemostatic dressings such as the and the  
10 bandages have proven useful in situations where it is possible  
to mechanically suppress the bleeding, they are expensive. The cheap,  
hemostatic powder was initially touted as the magic bullet in that it  
required only a sprinkling over the severely bleeding tissue or organ. However,  
concerns related to the high temperatures generated during the chemical process  
15 leading to hemostasis have limited its use to life-threatening situations only, and  
it is not recommended for use on soft internal tissues such as liver and spleen.  
Not surprisingly, medics in the recent Operations Enduring Freedom and Iraqi  
Freedom have therefore recommended that further R&D be performed to  
develop better solutions for the treatment of non-compressible hemorrhage.

20 We have recently attempted to develop a non-heparinized rat model of  
non-compressible liver hemorrhage (ACC 5\_04). However, this species possesses  
an enormous ability to control even massive bleeding (e.g., 30% total blood  
volume shed) without the need for further adjuncts, a finding recently confirmed  
by another scientist personal  
25 communication). The experiments described in the present protocol will be  
carried out under Business Line 3 Gel; 30dd05) as well as the MOM  
Thrust 6c (specifically in support of the Work Unit on Hemorrhage Control;  
16ci01).

Rabbit liver

### Objectives

The objectives of the present protocol are to establish a rabbit model of liver bleeding, and to determine the efficacy of two hemostatic agents in this model of non-compressible hemorrhage.

5

### Methods

Up to 225 male, New Zealand white rabbits, weighing 2.0 - 2.5 kg, will be obtained from We will use up to 10 rabbits to establish the liver injury model. If the pilot study is successful, up to 15 rabbits per experimental group tested (1 control group for each of the 3 studies listed in Table 1; 10 experimental groups; incl. 5 spare animals). The animals will be housed individually and allowed to adapt to the environmental conditions (22°C, 12 h light/dark cycle) for 2-3 days before undergoing surgery. Animals have free access to food and water until pre-anesthesia.

15

Table 1. Hemostatic agents or dressings to be tested

Study	Treatment	Sample size*	Name	Manufacturer	Formulation
A1	1-5	75	Hemostatic peptide (up to 5 doses)		powder
A2	6-8	45	Recombinant activated Factor VIIa (up to 3 doses; 75, 100 and 125 µg/kg body weight)		powder
B	9	15			gel
C	10-11	30	TIF material with peptide (up to 2 formulations; effective dose in study A)	DRDC Toronto	Gelatin-based material

\* Add 15 animals per study (n=45)

*Pilot study: development of the liver-resection model in the heparinized rabbit*

We intend to develop a simple, reproducible, heparinized liver injury model of uncontrolled, moderate hemorrhage recently described by [1]. Briefly, rabbits will be wrapped in a blanket and gently held to induce  
5 anesthesia (2.0% halothane: O<sub>2</sub>). Their abdomen will be clipped, depilated, and cleansed using standard procedures. Heparin (5 IU/mL in normal saline; will be administered through a 22 G i.v. catheter by continuous infusion syringe infusion pump model 55-4153; in the rabbit marginal ear vein at a rate of 1  
10 mL/min for 20 min. Following a 40-min waiting period to allow the coagulation parameters (i.e., activated partial thromboplastin time, APTT) to return to normal [1], a mid-line laparotomy will be performed. The left lateral lobe of the liver will then be gently positioned into a pre-weighed funnel leading into a 100-  
15 mL beaker. Care will be taken to keep the other lobes (i.e., right lateral, caudate, and median) outside the funnel during the entire study period by gently holding them back with a string of tubular elastic net bandage

We have previously determined that this method was very effective to isolate the left lateral lobe (unpublished data; ACC 5\_04). An area (40 mm x 4 mm) of the left lateral lobe will be marked with a ruler, then  
20 resected using curved scissors while holding the lobe between dry gauzes. A strip of pre-weighed, sterile, unmedicated 2-ply gauze will immediately be applied against the cut surface, and the bleeding will be monitored for the ensuing 30 min. This time period was selected based on [1], who have shown that the hemostasis  
25 is achieved within  $14 \pm 3$  min, with an average blood loss of  $49 \pm 7$  mL (i.e., approximately 30% of the total blood volume).

In an attempt to reduce the inter-individual variability in liver anatomy (and thus vascularity), blood loss (BL; in mL) will be standardized for the amount of liver tissue removed:

$$5 \quad BL = (1/Lobe_{resected}) * [(F_{30 \text{ min}} - F_0 \text{ min}) + (T_{30 \text{ min}} - T_0 \text{ min}) + (G_{30 \text{ min}} - G_0 \text{ min}) - V_A] \\ \text{Blood density}$$

where F, T and G correspond to the weights of the funnel, beaker and gauze, respectively;  $V_A$  is the volume of hemostatic agent solution used; and, the rabbit's blood density is 1.0431 g/mL [2]. The animals will be monitored for 30  
 10 min, after which period they will be humanely euthanized by intracardiac injection of T-61. The remaining portion of the left lateral lobe will then be dissected out and weighed. No mortality occurring within the 30-min bleeding period [1].

These experimental procedures will be performed initially in three rabbits.  
 15 This methodology is comparable to that described in [1], with the exception that these authors initiated their experimental treatment immediately following the cessation of the infusion period (while the APTT value was elevated to approximately three times the normal range). Their study also showed that no significant changes in APTT were observed over the 20-min  
 20 infusion period in a very lightly heparinized animal (i.e, using 0.2 IU/mL), the total blood loss and bleeding times averaging  $18 \pm 9$  mL (i.e., 10% total blood loss) and  $6 \pm 2$  min, respectively. As the half-life of heparin is relatively short in the rabbit [3], it is possible that we measure comparable values to those stated in the lightly heparinized rabbit model above, despite initially using a higher  
 25 heparin concentration, as the APTT will have returned to close to a normal value during the 40-min waiting period. If this is the case, we will then opt to initiate the treatment immediately after completion of the infusion procedures in the remaining 7 animals, while the APTT values remain presumably high. One may then question the relevance of this model to the battlefield scenario (i.e., non-



heparinized casualty). However, to our knowledge, all current animal models of liver [1] or kidney injury [4] have involved heparinized animals, likely due to the difficulty in otherwise ensuring that large volumes of blood (comparable to those expected in battlefield casualties) will be lost. Nevertheless, this animal model would remain highly relevant to the clinical setting as it will mimick the conditions following a full heparinization prior to hepatic surgery. The pilot will be judged successful and testing will proceed if a reproducible blood loss can be measured (i.e., coefficient of approx 10%; 25-30% blood volume shed).

10 *Experimental protocol for testing an hemostatic agent or wound dressing using the liver injury wound model*

Liver injury will be induced in the anesthetized rabbits, as described above. No blood will be removed from the damaged liver surface before application of the dressing or hemostatic agent under study. The liver should be actively bleeding when the experimental treatment is applied. A pre-weighed amount of \_\_\_\_\_ will be applied on a sterile gauze. Alternately, the gauze will be pre-moistened with a solution containing various concentrations of the peptide or Factor VIIa. Additional volumes of these agents or saline will be applied to the blood-drenched gauze (using a syringe) every 30 s for the first 5 min due to expected loss of agent through turbulence. Animals will be monitored for 30 min after application of the gauze to the wound, as described previously.

Pre-screening of the hemostatic properties of treatments #1-8 will be performed in 80 rabbits (n=10 per treatment). Recombinant activated Factor VIIa has been shown repeatedly to be hemostatic when injected systemically at doses ranging from 75-125 µg/kg body weight [5-6]. To our knowledge, this agent has never been applied topically. However, it is known that application of anti-Factor VIIa will induce thrombolysis [7]. Recent *in vitro* data has shown that the

contractor-designed peptide is hemostatic (DRDC Toronto, personal communication). If no significant hemostatic effect is apparent in Study 1A compared to non-treated animals, no further testing of treatments #1-5 will be performed, and study C will not be performed. Alternately, sample size will be increased to 15 in the event that these treatments exert a nearly significant hemostatic effect when applied to the injured liver. Furthermore, if the result is already significant ( $p < 0.05$ ) at the smaller sample size (i.e.,  $n=10$ ), no further animals will be tested. If deemed hemostatic, the peptide will be incorporated into the DRDC dressing material at its maximum effective dose. Their ability to diffuse through the material and exert their hemostatic effect will be tested using the liver injury model ( $n=8$ ). Sample size will be increased to fifteen if the hemostatic effect measured is significant, to achieve statistical significance. Furthermore, if the result is already significant at the smaller sample size, no further animals will be tested.

15

#### *Statistical analysis*

Statistical analyses will be completed using Statistica (Version 6.1, Statsoft, Inc.). In each study, a one-way analysis of variance will be used to determine statistical significance among groups for respective differences in hemostatic efficacy. When statistical significance will be determined, a Neumann-Keuls post-hoc analysis will be performed to locate significant differences. Significance will be deemed to exist when  $p < 0.05$ .

25 REFERENCES

30

## form F [2004-06]

“to establish a non-lethal model of contaminated open wounds in pigs.” : up to 21 Yorkshire pigs

justification for species: “The pig is used extensively in animal models of wound healing since pig skin is very similar to that of humans.”

involves hazardous biological agents Ps. aerughosa, Staph.epidermis, and Fusobacterium necrotum

“wound contamination characteristics over a 21-d study period.”

“Two samples will be taken (using a 4-mm biopsy punch) from pre-selected wounds . . . on days 0, 1, 3, 7, 10, 14, 17 and 21, with the animal under general anesthesia”

animals to be euthanized at end of 21 days using T61 (i.v.) following sedation

s.15(1)

s.17

s.19(1)



**DCIEM**

**ANIMAL USE PROTOCOL**

PROTOCOL NO. **2/04**

FOR OFFICE USE ONLY  
Expiry Date

**1**

Surname	First Name	Initial
Rank/Position DS 4	Section OMS	Group Trauma
DCIEM Telephone	Residence Telephone	
NAME OF DESIGNATED ALTERNATE(S) FOR EMERGENCIES		
Name	DCIEM Telephone	Residence Telephone
Name	DCIEM Telephone	Residence Telephone

**2**

Title

Establishment of a non-lethal model of full thickness, contaminated wounds in pigs

**3**

PROPOSED START DATE OF RESEARCH	Day 01	Month Sep	Year 2004
EXPECTED DATE OF COMPLETION	Day 31	Month Dec	Year 2006

**4**

CATEGORY OF INVASIVENESS (Refer to Canadian Council on Animal Care Categories A, B, C, D, E).

B. Shaving (under anaesthesia)       B. Wound Injury (under anaesthesia)

B. Pre-med, mild discomfort, i.m. Injection       D. Recovery from wound Injury

LIST EACH experimental condition or manipulation that could cause pain or discomfort in the conscious animal and for each indicate the expected degree of pain/discomfort using the CCAC Codes.  
FOR EACH, indicate (by checking the box) the conditions that will be alleviated and ensure that the drugs to be used are stated in Section 13 and procedures described in Section 6.

**5**

TYPE OF EXPERIMENT       Research       Testing

SURGICAL     Acute     Survival      NON-SURGICAL     Acute     Chronic

FUNDING SOURCE NUMBER: 16ca18~~2307305~~ (i.e., Financial Coding, WBE)

PEER REVIEWED     YES     NO      IF YES, ATTACH REVIEW DOCUMENTATION.

This protocol has been used extensively in the laboratories of

IF PROTOCOL IS SUBMITTED BETWEEN SCHEDULED ACC MEETINGS, IT MAY BE GIVEN 'PROVISIONAL' APPROVAL BY THE CHAIR, SECTION HEAD, VETERINARIAN, AND COMMUNITY MEMBER COLLECTIVELY. A COPY, HOWEVER, MUST BE SUBMITTED TO ALL MEMBERS OF THE COMMITTEE AT THAT TIME FOR FORMAL APPROVAL AT THE NEXT MEETING.

---

**6 DESCRIPTION OF PROJECT AND PROCEDURES.** Describe in **DETAIL** all procedures, techniques to be used; emphasizing those performed on animals. Append additional page(s) as necessary.

See Annex A.

and/or veterinarian technician will be responsible for performing all pre-operative procedures, Incl. anesthesia induction; analgesic administration. will also be responsible for performing all wound injury procedures.

Co-op students will be responsible for preparation of gel formulations, dressing materials, etc., care of animals during acclimation period, and post-operative observation of the animals.

s.15(1)

s.17

**7 IDENTIFY THE PRIMARY OBJECTIVE(S) OF THE PROJECT.** In layman's terms, please summarize the primary objective(s) and benefit(s) expected from the study.

To establish a non-lethal model of contaminated open wounds in pigs. This model will be useful in future studies to evaluate the efficacy of wound care agents, including dressings and antiseptics.

**8 RESEARCH STAFF**

Name	Prof	Tech	PD	Grad	UnderGrad	Term	Training
	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Veterinary Technician (VET)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Co-op students	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Note: University one-day course, at minimum, is mandatory for all personnel, including students, post-docs, visiting fellows, RAS. Check if the individual has completed this or equivalent training.  
 Note: The appended experimental methods should indicate the responsibilities of each individual listed above.

**9 ANIMALS**

Animal Species (Common Name)	Total Number of Animals	Source of Animals
Yorkshire Pig	Up to 21	

**10 JUSTIFICATION FOR:** A. Species (see Note 1) and B. Number of Animals Used (See Note 2)

- A. The pig is used extensively in animal models of wound healing since pig skin is very similar to that of humans.
- B. The number of animals should yield sufficient data for completing statistical analysis.

Note 1: Is the choice of animal the most scientifically appropriate one, and of the lowest level of sentience consistent with the Objectives? Justified in Section 6, Annex A paragraph 2.  
 Note 2: Is the number of animals based on a plan incorporating statistical considerations that ensure sufficient, but not Excessive numbers for drawing reliable conclusions? Justified in Section 6 para 2.3.1.2.

**11 ALTERNATIVES:** Are non-animal alternatives available for this project?  YES  NO

**12 SPECIAL ANIMAL CARE REQUIREMENTS.** Specify, if any, special housing, nutritional, temperature, lighting, post-operative care or other facilities or conditions that are or may be required.

See Annex A. Daily injection of long-lasting analgesics for 21 d or as required.

SPECIFY ANIMAL HOUSING ROOM 1418

SPECIFY EXPERIMENTAL SITE ROOM 1404

**13 DRUGS FOR ANAESTHESIA/ANALGESIA**  
 Is Anaesthesia to be used?  YES  NO      Is Analgesia to be used?  YES  NO

If yes, complete Section 13 below. If no to either, justification is in Section 6 para

	DRUG	DOSAGE	ROUTE OF ADMINISTRATION
A. Pre-Anaesthesia	<u>ketamine</u>	<u>1.5mg/kg BW</u>	<u>im</u>
Pre-Anaesthesia	<u>acepromazine</u>	<u>0.5mg/kg BW</u>	<u>im</u>
B. Anaesthesia	halothane/N2O	to effect	inhalation
Anaesthesia			
C. Pre-Analgesic	buprenorphine	<u>0.1-0.3mg/kg BW</u>	<u>im</u>
Post-Analgesic	<u>buprenorphine</u>	<u>0.1-0.3mg/kg</u>	<u>im</u>
D. Other			

POST-OPERATIVE CARE needs defined in Section 12 are fully detailed in Section 6 para Annex A p 4, 1 13-15.

**14 EUTHANASIA**

- Anaesthetic overdose (sedation with ketamine acepromazine (1m) then 1.5 at 6)      NOTE: Physical euthanasia can be used only with pre-anaesthesia. If this is not possible, justification must be included:
- Cervical Dislocation       Decapitation       Pithing       Other
- Exsanguination (under Anaesthesia)      IF NOT EUTHANIZED, please indicate how and where disposed of:
- Stunning
- Carbon Dioxide

**15 HAZARDOUS AGENTS AND PRECAUTIONS**

- Specify each Agent and Potential Hazard (include amount, route, and Frequency of admin, precautions OR indicate if included in Section 6). NOT APPLICABLE
- Biological      Ps. aeruginosa, Staph. epidermis, Fusobacterium necroform
- Chemical
- Carcinogen
- Radiosotope/Radiation (include R/A Permit No. and Expiration Date)

NOTE: If special precautions are required, ensure these are detailed in Section 12.

**16 ENDPOINTS**  
 Specify Endpoints and Criteria (in detail):

All animals will be closely examined and weighed daily. Animals that will lose more than 15% of their body weight, show signs of withdrawal, abnormal breathing rate, fever or undue pain or distress will be euthanized.

Defining humane endpoints is imperative if the project will lead to pain or discomfort or any physical or physiological abnormality that would affect the animal's well-being. The criteria that will be employed to remove the animal from the study and euthanized prior to the onset of unrelievable pain or distress, moribundity or death MUST be stated here and in the protocol.

**DECLARATION**

All animals in this research/testing proposal will be maintained and used in accordance with the recommendations of the Canadian Council on Animal Care, the requirements under the Animals for Research Act, R.S.O. 1980, and the DCIEM Animal Care Policies And Guidelines, and other applicable DCIEM policies and procedures.

Principal Investigator

Date

*18 May 04*

**MANAGEMENT APPROVAL**

Section or Group Head

Date

*18 May '04*

**ANIMAL CARE COMMITTEE APPROVAL**

Chair/Animal Care Committee

Date

*18 May 04*

DCIEM Consultant Veterinarian

Date

*May 18/04*

**OBSERVATIONS, RESTRICTIONS OR CONDITIONS** (as applicable). INCLUDE THE NEED FOR (and details of) EXTERNAL PEER REVIEW.

*APPROVED WITH THE CHANGE OF ANALGESIC FROM BUPRENORPHINE I.M. TO PHENTINOL PATCH.*

THIS PROTOCOL IS APPROVED FOR THE PERIOD SPECIFIED IN SECTION 3. IT WILL BE REVIEWED SEMI-ANNUALLY AT SCHEDULED DCIEM ACC MEETINGS. IF AN EXTENSION IS REQUIRED, A FORMAL AMENDMENT TO THE PROTOCOL MUST BE SUBMITTED FOR APPROVAL BY THE SECTION HEAD, CHAIR AND VETERINARIAN.





that model, twenty wounds are contaminated with ATCC strains of *Pseudomonas aeruginosa*, *Staphylococcus epidermis*, and *Fusobacterium sp.* Our intent is to develop this model using *Ps. aeruginosa*, *Staph. epidermis*, and *Fusobacterium sp.* strains previously isolated from pig wounds. It has been shown that bacteria passed previously in a host have enhanced virulence characteristics, likely due to an activation of the bacteria by repeated exposure to the immune cells of the host (personal communication). This trauma model will be used in future studies to evaluate the efficacy of wound-care agents.

## 10 *Methods*

Up to 21 male Yorkshire pig (15-20 kg) will be obtained from

Experiments will be conducted using up to three pigs at a time, to ascertain the adequacy of the various technical procedures involved (e.g., wound covering, number of biopsies per wound, bacterial challenge, etc.) as well as wound contamination characteristics over a 21-d study period. After the first pair of pigs has undergone the wound sampling protocol (see below), data will be analyzed to determine:

- whether the inoculum concentration is sufficient to ensure that the wound bacterial counts are at least  $10^5$  CFU/g tissue (i.e., clinical infection threshold);
- how many samples of a given wound are required to offer a representative assessment of wound bacterial count (intra-wound contamination variability should be < 10%);
- how many wounds must be sampled at a given time point to provide a representative assessment of overall wound contamination (inter-wound contamination variability should be < 10%);
- whether a 21-d study period is sufficient to allow wound closure or is too long.

It is also noteworthy that the *Ps. aeruginosa* and *Staph. epidermidis* bacteria isolated from the pig wounds will be stored using standard microbiological procedures and will be used for the establishment of the porcine model. Experimental parameters will be re-adjusted, as required, and the revised  
5 protocol will be applied to another pair of pigs. Ideally, the final wound sampling parameters selected should not only optimize the assessment of wound bacterial contamination, but also aim to minimize disturbance of the wound healing process. It is expected that the final protocol be tested on 6 pigs, to ensure that the data are reproducible.

10

The animals will be allowed to adapt to the environmental conditions (20-25°C, 12 h light/dark cycle) for at least 7 days before undergoing surgery. Animals will be housed individually, and have free access to pig chow and water at all times during the study period. The study will be conducted in accordance  
15 with the guidelines from the Canadian Council on Animal Care (CCAC).

### ***Bacterial challenge***

Isolates of *Ps. aeruginosa* (i.e., a Gram-negative bacteria), *Staph. epidermis*  
20 (i.e., a Gram-positive bacteria), and *Fusobacterium sp.* (an anaerobe) will be used to infect the wounds. The bacterial strains will be grown at 37°C in nutrient broth for 18 h in a shaking water bath to obtain a log-phase growth culture. The suspensions will be washed three times in sterile phosphate-buffered saline (PBS), re-suspended in sterile PBS, and diluted to approximately  $10^7$  colony  
25 forming units (CFU) per mL. Serial dilutions will be plated on Pseudomonas Isolation agar (PIA; for *Ps. aeruginosa*), Staphylococcus Medium 110 (SM110; for *Staph. epidermis*) or Tryptic Soy agar (TSA; for *Fusobacterium*) to assess bacterial concentrations in the inoculum. On the experimental day, the three bacterial cultures will be mixed together in a ratio approximating 1:1:0.5 (*Pseudomonas*:  
30 *Staphylococcus*: *Fusobacterium*;  $10^7$  CFU in 50 mL).

s.15(1)

s.17

### *Surgical Procedures*

On the experimental day, each pig will be pre-anesthetized with ketamine (15 mg/kg body weight, i.m.) and acepromazine (0.5 mg/kg body weight, i.m.) followed by gas inhalation (oxygen: 1-2% isoflurane). The dorsal and lateral thorax will be clipped, and the skin prepared for wounding by washing with an antibiotic-free soap. Columns of wounds on the dorsum will be labeled (using an indelible marker) as A through D, and rows marked as 1 through 4. Sixteen full-thickness (down to the deep fascia) wounds will be created using a 3-cm diameter tissue trephine. Wounds will be made 4 cm apart, with columns B & C set 2 cm on each side of the pig's spine. Sterile gauze compresses (

will be applied on the wounds, soaked with a saline/epinephrine solution (1:100 v/v), and allowed to remain *in situ* until complete haemostasis has occurred. Each wound will then be measured in two directions using digital calipers, to ascertain the initial wound area, and digitally photographed.

The wounds will be loosely packed with 2.5 cm x 2.5 cm sterile gauzes and inoculated with 3 mL the bacterial suspension. The wounds will then be covered for 20 min with an occlusive film to prevent drying. At the end of the infection period, the gauzes will be removed, and the wounds will be covered with a piece of sterile absorbent gauze ( Layers of adhesive PVC tape ( will then be applied to the back of the pig to hold down firmly the gauze dressings. The entire trunk of the pig will finally be wrapped with a layer of elastic adhesive bandage ( self-adhesive bandage,

A dose of narcotic (i.m. buprenorphine, 0.1-0.3 mg/kg body weight) will be administered before returning the animal to its pen, and twice daily thereafter for 21 d, or as required. Pigs will be followed closely for 3 h to ensure that no deaths be attributed to anesthesia or open wound injury *per se*. However, no

s.15(1)

s.17

5

mortality is expected after completing these procedures (personal communication). Nevertheless, CCAC guidelines for judging morbidity and moribundity will be used to assess the animal's health status, if necessary. Thus, ~~the animals will be humanely euthanized before the end of the 21-d study period~~ if the nature of the signs of illness, their rate of onset and persistence strongly suggest an impending death. Inclusion of subjective (e.g. withdrawal, breathing rate, mobility) and objective measurements (e.g. food and water intake) will facilitate the monitoring of the animal's health status.

10 *Experimental Protocol*

Two samples will be taken (using a 4-mm biopsy punch) from pre-selected wounds (see sampling schedule below) on days 0, 1, 3, 7, 10, 14, 17 and 21, with the animal under general anesthesia. All but three wounds will be sampled 4 times over the 21-d study period, with at least 7 days between 2 consecutive wound samplings. Wounds A3, B2 and C4 will not be sampled, to provide an estimation of the normal time required for healing to be completed (in the absence of biopsies). Prior to sampling, the size of the wound will be measured in two directions, and photographs will be taken. Wounds will then be covered as previously described. Tissues will be placed into pre-weighed 20 tubes, homogenized in cold PBS, and plated serially on SM110 and PIA to determine the microbiological counts. The sampling schedule will be as follows:

Wound sampling procedure

- Day 0            Wounds A1 A1 A1 D3 D3 D3  
                      B1 A2 B3 C1 D1 C2
- 5            Day 1            Wounds B1 A2 C2 D2 D4 A4
- Day 3            Wounds B3 C1 D1 D3 C3 A4
- 10          Day 7            Wounds B1 A2 C2 D2 D4 B4
- Day 10           Wounds B3 C1 D1 C3 A4 B4
- Day 14           Wounds C2 D2 D4 C3 A4 B4
- 15          Day 17           Wounds B1 A2 D1 C3 B4
- Day 21           Wounds A1 B3 C1 D2 D4

20            Animals will be humanely euthanized at the end of the 21-d study period using T61 (i.v.) following sedation (ketamine, 15 mg/kg body weight; acepromazine, 0.5 mg/kg body weight, i.m.).

25    REFERENCES

30

**Page 147**

**is withheld pursuant to section  
est retenue en vertu de l'article**

**17**

**of the Access to Information Act  
de la Loi sur l'accès à l'information**

## **form G [2004]**

ammendment to porcine protocols? indicates the DRDC has authorized a Contractor for “testing in porcine models of injury the in vivo bactericidal efficacy (full-thickness infected wounds) and wound healing properties”

these are tests for “four different DRDC materials developed under a Technology Investment Fund”



s.15(1)

s.17

## Amendment #1 to protocol ACC 2/04

### Background information

We have recently issued a contract to (W7711-05-7958) for testing in porcine models of injury the *in vivo* bactericidal efficacy (full-thickness infected wounds) and wound healing properties (partial-thickness wounds as per ACC 4/04) of the four different DRDC materials developed under a Technology Investment Fund (16ci04).

However, the preparation of the different types of DRDC materials remains very time-consuming despite our efforts to scale-up the process, and we must be careful not to "waste" any material. Furthermore, we intend to use similar technical procedures to secure the materials during the different studies that will be performed by the Contractor. We will thus combine the two different models on a same animal, keeping the total area to be injured in a given animal (i.e. full- and partial-thickness wounds) at least 4 times below those previously accepted under ACC 2/04 (i.e., 113 cm<sup>2</sup>; 16 wounds of full-thickness wounds of 3-cm diameter) and ACC 4/04 (i.e., 80 cm<sup>2</sup>; 80 partial-thickness wounds of 1 cm<sup>2</sup>).

This pilot study (1 pig) will allow us to determine the type of commercial tape that should cover the materials to ensure the full the recovery of the material after 1 day. It will also indicate whether the size of the material applied to the partial-thickness wounds is appropriate, as we do not know whether the material will shrink or expand during the 3-d period. Lastly, we will determine whether puffs and meshes undergo any significant degradation over a 24-h period, as suggested by our *in vitro* testing [1]. No harvesting of the partial-thickness wounds will be performed throughout the experiment.

### Amendments to Protocol 2/04

1. Create 14 partial-thickness wounds on the left side of the animal (1 cm<sup>2</sup>; total area 14 cm<sup>2</sup>).
2. Apply 1 strip of the following dressings over 5 wounds:
  - a. Wet Aam IPN films (1 strip; 5 wounds)
  - b. Freeze-dried benchmark IPN films (1 strip; 4 wounds)
  - c. Wet benchmark IPN films (1 strip; 5 wounds)
3. Cover the wounds with a sterile sheet of dressing then adhesive PVC tape ( This set-up will allow easy removal of the material after 24 h.
4. Create 8 full-thickness wounds on the right side of the animal (10 mm diameter; total area 6 cm<sup>2</sup>).

s.15(1)

s.17

5. Infect 4 full-thickness wounds using ATCC strains of *Pseudomonas aeruginosa* and *Staphylococcus epidermis* similar to those used by the Contractor. Note that *Fusobacterium sp.* will not be used as the Contractor's model does not include this bacterial strain.
6. Pack loosely the 4 wounds with 0.5 cm x 0.5 cm sterile gauzes, and inoculate them with 0.5 mL of the bacterial suspension for 20 min.
7. Cover the wounds for 20 min with an occlusive film ( ) to prevent drying. At the end of the infection period, remove the gauzes.
8. Place either a re-moistened DRDC messy puff or a DRDC IPN mesh (n=4 per material) directly in the wounds.
9. Repeat step 3 as described above.
10. Wrap the entire trunk of the pig with a layer of elastic adhesive bandage ( ) self-adhesive bandage.
11. After a 24-h period, re-anesthetize the animal:
  - a. compare the status of the puffs and meshes in the non-inoculated and inoculated wounds (e.g., degradation, presence of exudates, etc.)
  - b. observe the status of the two types of films (e.g., shrinkage, swelling, etc.)
12. Cover the full-thickness wounds with sterile gauze then ( ). No further observations will be made.
13. Re-apply the same dressings on the partial-thickness wounds and repeat step 3 above.
14. Re-anesthetize the animals at 48 and 72 h post-injury to observe the wounds and status of the dressings covering the partial-thickness wounds, replacing the restraining system (i.e., ( ), tape, and ( ).
15. Humanely euthanize the animal.

## REFERENCE

- 1.

## Amendment #2 to protocol ACC 2/04

### Background information

We have recently tested the different DRDC polymeric films in a pig model of partial-thickness wounds (amendment #1 to protocol ACC 4/04) and determined that the re-moistened DRDC material should be applied to the partial-thickness wounds to prevent their complete degradation. Furthermore, the data also suggested that the use of a semi-permeable membrane (such as \_\_\_\_\_ to cover the re-moistened DRDC material might be preferable to using an \_\_\_\_\_ wound cover as the material's texture was somewhat altered after 24 h.

This study is designed to:

- indicate whether the size of the material applied to the partial-thickness wounds (i.e., strips) is appropriate, as we do not know whether the material will shrink or expand;
- determine the best method for freeze-drying the puffs and meshes (complete coverage, ease of insertion and handling, etc.)
- determine the 24-h bactericidal efficacy of mafenide acetate-loaded puffs and meshes.

No harvesting of the partial-thickness wounds will be performed throughout the 2-d experiment, as the Contractor will not assess wound healing until day 4 post-injury.

### Amendments to Protocol 2/04

1. Create 10 partial-thickness wounds on the left side of one pig (1 cm<sup>2</sup>; total area 10 cm<sup>2</sup>).
2. Apply 1 strip of the following dressings over 5 wounds:
  - a. Re-moistened Aam IPN film (1 strip; 5 wounds)
  - b. Re-moistened benchmark IPN film (1 strip; 5 wounds)
3. Cover the wounds with: a sterile sheet of \_\_\_\_\_ dressing \_\_\_\_\_; sterile gauze; and, adhesive cotton tape \_\_\_\_\_ This set-up will allow easy removal of the material after 24 h.
4. Create 18 full-thickness wounds on the right side of the animal (8 mm diameter; total area 9 cm<sup>2</sup>).
5. Infect 4 full-thickness wounds using ATCC strains of *Pseudomonas aeruginosa* and *Staphylococcus epidermis* similar to those used by the Contractor.

s.15(1)

s.17

Table 1. Types of Meshes and Puffs tested

**Puffs:**

Label	Type	Freeze-Drying Procedure
P1	Loaded FD	15mL test tube with 5mL on top
P2	loaded FD	15mL test tube with 5mL on top
P3	loaded REM	15mL test tube with 5mL on top
P4	loaded REM	15mL test tube with 5mL on top
P5	loaded FD	50mL falcon tube with 15mL test tube on top (vertical)
P6	loaded FD	50mL falcon tube with 15mL test tube on top (vertical)
P7	unloaded REM	50mL falcon tube with 15mL test tube on top (vertical)
P8	unloaded REM	50mL falcon tube with 15mL test tube on top (vertical)

**Meshes:**

Label	Type	Freeze-Drying Procedure
M1	loaded FD	laid flat on a plastic mesh
M2	loaded REM	laid flat on a plastic mesh
U1	unloaded REM	laid flat on a plastic mesh
M3A	loaded FD	15mL test tube with 5mL test tube on top
M3B	loaded FD	15mL test tube with 5mL test tube on top
M4A	loaded REM	15mL test tube with 5mL test tube on top
M4B	loaded REM	15mL test tube with 5mL test tube on top
M5A	loaded FD	50mL falcon tube with 15mL test tube on top (vertical)
M5B	loaded FD	50mL falcon tube with 15mL test tube on top (vertical)
U2A	unloaded REM	50mL falcon tube with 15mL test tube on top (vertical)
U2B	unloaded REM	50mL falcon tube with 15mL test tube on top (vertical)

REM - remoistened FD - freeze-dried.

2. Apply one 15-mm disc of the following dressings on each wound:
  - a. Re-moistened Aam IPN film (n=9)
  - b. Re-moistened benchmark IPN film (n=9)
3. Cover the wounds with: a sterile sheet of \_\_\_\_\_ dressing ( ); sterile gauze; and, adhesive cotton tape \_\_\_\_\_ This set-up will allow easy removal of the material after 24 h.
4. Create 8 full-thickness wounds on the right side of the animal (6 mm diameter; total area 2 cm<sup>2</sup>).
5. Place one of the dressings described in Table 1 in each of the wounds.
6. Repeat step 3 as described above.
7. Wrap the entire trunk of the pig with a layer of elastic adhesive bandage ( \_\_\_\_\_ self-adhesive bandage).
8. After a 24-h period, re-anesthetize the animal:
  - a. Remove the films covering the full-thickness wounds, and make observations (adherence to wounds, appearance of 3D structures, ease of removal, excessive presence of exudate, etc.)
  - b. Cover the new full-thickness wounds with sterile gauze then PVC \_\_\_\_\_ No further observations will be made.
  - c. Remove the films covering the partial-thickness wounds, and make observations (adherence to wounds, expansion/shrinkage of discs, etc.)
  - d. Re-apply the same films on the partial-thickness wounds (as the Contractor's study will call for leaving the dressings unaffected for 4 days post-injury) and repeat step 3 above.
9. Re-anesthetize the animals at 72 h post-injury and repeat steps 8 (c) and 8 (d), paying special attention to the integrity of the material after being left unattended for 48 h.
10. Humanely euthanize the animal.

s.17

Table 1 Types of meshes and puffs tested

Cut	Code	Freeze-drying procedure
half puff	P1A	15mL test tube
	P1B	50mL Falcon tube
half mesh	M1A	15mL test tube
1/3 mesh	M2A	5mL test tube
	M2B	15mL test tube
1/3 mesh	M3A	Eppendorf tube (top)
	M3B	HPLC vial top
1/3 mesh	M4A	Eppendorf tube (middle)
	M4B	Eppendorf tube (bottom)

REFERENCES

- 1.